DUBLIN--(BUSINESS WIRE)--The "Global Gastrointestinal Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Gastrointestinal Partnering 2012 to 2018 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.
The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Gastrointestinal dealmaking
Chapter 3 - Financial deal terms for Gastrointestinal partnering
Chapter 4 - Leading Gastrointestinal deals and dealmakers
Chapter 5 - Gastrointestinal contract document directory
Chapter 6 - Gastrointestinal dealmaking by therapeutic target
For more information about this report visit https://www.researchandmarkets.com/research/l6vvmw/global?w=4